Gracell Biotechnologies Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego and suzhou, china and shanghai, china, feb. 22, 2024 (globe newswire) -- gracell biotechnologies inc. (“gracell” or the “company”, nasdaq: grcl), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by astrazeneca, in accordance with the terms and conditions of the agreement and plan of merger, dated as of december 23, 2023 (the “merger agreement”), by and among the company, astrazeneca treasury limited, a private limited company incorporated under the laws of england and wales (“parent”), and grey wolf merger sub (“merger sub”), an exempted company with limited liability incorporated under the laws of the cayman islands and a wholly owned subsidiary of parent...

San diego and suzhou, china and shanghai, china, feb. 20, 2024 (globe newswire) -- gracell biotechnologies inc. (“gracell” or the “company”, nasdaq: grcl), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “egm”) held on february 19, 2024, the company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the company of the previously announced agreement and plan of merger, dated as of december 23, 2023 (the “merger agreement”), by and among the company, astrazeneca treasury limited, a private limited company incorporated under the laws of england and wales (“parent”), and grey wolf merger sub, an exempted company with limited liability incorporated under the laws of the cayman islands and a wholly owned subsidiary of parent (“merger sub”), the plan of merger required to be filed with the registrar of companies of the cayman islands (the “plan of merger”), and the other agreements or documents contemplated by the merger agreement or any document or instrument delivered in connection thereunder (the “transaction documents”) to which the company is a party and the consummation of the transactions contemplated by the merger agreement (including the merger) and the contingent value rights agreement, in the form attached as exhibit b to the merger agreement, (collectively, the “transactions”), upon the terms and subject to the conditions set forth therein...

Further expands clinical development of fastcar-t gc012f in multiple myeloma amid ongoing u.s. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma further expands clinical development of fastcar-t gc012f in multiple myeloma amid ongoing u.s. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of gracell biotechnologies inc. (nasdaqgs: grcl) to astrazeneca. under the terms of the proposed transaction, shareholders of gracell will receive $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ads of gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (.

New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of gracell biotechnologies inc. (nasdaq: grcl) to astrazeneca is fair to gracell shareholders. under the terms of the proposed transaction, astrazeneca will acquire gracell for $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ads of gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ads of gracell) payable.

Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie - CFO Conference Call Participants Yigal Nochomovitz - Citi Benjamin Burnett - Stifel Dev Prasad - Jefferies Eric Schmidt - Cantor Emily Bodnar - H.C. Wainwright Yanan Zhu - Wells Fargo Securities Joseph Catanzaro - Piper Sandler Justin Zelin - BTIG Operator Ladies and gentlemen, thank you for standing by.

Gracell Biotechnologies (GRCL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November. Stifel 2023 Healthcare Conference Fireside Chat: Tuesday, November 14th at 1:15 pm ETOne-on-one meetings: November 14th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Jefferies London Healthcare Conference Fireside Chat: Wednesday, November 15th at 11:30 am GMT / 6:30 am ETOne-on-one meetings: November 15th and 16th, 2023Presenter: Dr...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.